These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28727494)

  • 1. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
    Zhao Y; Xiao J; Yang R; Wu R; Hu Y; Beckmann H; Wu J; Hou Q; Sun J
    Pediatr Hematol Oncol; 2017 Apr; 34(3):138-148. PubMed ID: 28727494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
    Collins P; Faradji A; Morfini M; Enriquez MM; Schwartz L
    J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.
    Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
    Curr Med Res Opin; 2017 Jul; 33(7):1223-1230. PubMed ID: 28326849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).
    Manco-Johnson MJ; Kempton CL; Reding MT; Lissitchkov T; Goranov S; Gercheva L; Rusen L; Ghinea M; Uscatescu V; Rescia V; Hong W
    J Thromb Haemost; 2013 Jun; 11(6):1119-27. PubMed ID: 23528101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
    Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
    Powell J; Martinowitz U; Windyga J; Di Minno G; Hellmann A; Pabinger I; Maas Enriquez M; Schwartz L; Ingerslev J;
    Thromb Haemost; 2012 Nov; 108(5):913-22. PubMed ID: 23014711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study.
    Lalezari S; Coppola A; Lin J; Enriquez MM; Tseneklidou-Stoeter D; Powell J; Ingerslev J;
    Haemophilia; 2014 May; 20(3):354-61. PubMed ID: 24847524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study.
    Yao W; Xiao J; Cheng X; Feng G; Li C; Zhang X; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Zhao Y; Wu R
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):851-858. PubMed ID: 27920236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
    Simpson ML; Desai V; Maro GS; Yan S
    J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China.
    Shi J; Zhao Y; Wu J; Sun J; Wang L; Yang R
    Haemophilia; 2007 Jul; 13(4):351-6. PubMed ID: 17610547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
    Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
    Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
    J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
    Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.
    Abshire TC; Brackmann HH; Scharrer I; Hoots K; Gazengel C; Powell JS; Gorina E; Kellermann E; Vosburgh E
    Thromb Haemost; 2000 Jun; 83(6):811-6. PubMed ID: 10896230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life evidence in evaluating effectiveness of treatment in Haemophilia A with a recombinant FVIII concentrate: a non-interventional study in emerging countries.
    Gouider E; Rauchensteiner S; Andreeva T; Al Zoebie A; Mehadzic S; Nefyodova L; Brunn M; Tueckmantel C; Meddeb B
    Haemophilia; 2015 May; 21(3):e167-e175. PubMed ID: 25649665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S; Maro GS; Desai V; Simpson ML
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.
    Mahlangu J; Kuliczkowski K; Karim FA; Stasyshyn O; Kosinova MV; Lepatan LM; Skotnicki A; Boggio LN; Klamroth R; Oldenburg J; Hellmann A; Santagostino E; Baker RI; Fischer K; Gill JC; P'Ng S; Chowdary P; Escobar MA; Khayat CD; Rusen L; Bensen-Kennedy D; Blackman N; Limsakun T; Veldman A; St Ledger K; Pabinger I;
    Blood; 2016 Aug; 128(5):630-7. PubMed ID: 27330001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare - a retrospective, phase IV, non-interventional study.
    Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu V; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
    Curr Med Res Opin; 2017 Sep; 33(9):1571-1578. PubMed ID: 28532239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.